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Abstract
Objective:  to  prospectively  validate  a  previously  constructed  transcutaneous  bilirubin  (TcB)
nomogram for  identifying  severe  hyperbilirubinemia  in  healthy  Chinese  term  and  late-preterm
infants.
Methods:  this  was  a  multicenter  study  that  included  9,174  healthy  term  and  late-preterm
infants in  eight  hospitals  of  China.  TcB  measurements  were  performed  using  a  JM-103  biliru-
binometer.  TcB  values  were  plotted  on  a  previously  developed  TcB  nomogram,  to  identify  the
predictive  ability  for  subsequent  signiﬁcant  hyperbilirubinemia.
Results:  in  the  present  study,  972  neonates  (10.6%)  developed  signiﬁcant  hyperbilirubinemia.
The 40th percentile  of  the  nomogram  could  identify  all  neonates  who  were  at  risk  of  signiﬁcant
hyperbilirubinemia, but  with  a  low  positive  predictive  value  (PPV)  (18.9%).  Of  the  453  neonates
above  the  95th percentile,  275  subsequently  developed  signiﬁcant  hyperbilirubinemia,  with  a
high  PPV  (60.7%),  but  with  low  sensitivity  (28.3%).  The  75th percentile  was  highly  speciﬁc  (81.9%)
and  moderately  sensitive  (79.8%).  The  area  under  the  curve  (AUC)  for  the  TcB  nomogram  was
0.875.
 Please cite this article as: Yu Z, Han S, Wu J, Li M, Wang H, Wang J, et al. Validation of transcutaneous bilirubin nomogram for identifying
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∗ Corresponding author.
E-mail: chen6010@163.com (C. Chen).
0021-7557  © 2014 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. 
http://dx.doi.org/10.1016/j.jped.2013.08.013
Este é um artigo Open Access sob a licença de CC BY-NC-ND
274  Yu  Z  et  al.
Conclusions:  this  study  validated  the  previously  developed  TcB  nomogram,  which  could  be  used
to predict  subsequent  signiﬁcant  hyperbilirubinemia  in  healthy  Chinese  term  and  late-preterm
infants.  However,  combining  TcB  nomogram  and  clinical  risk  factors  could  improve  the  predictive
accuracy  for  severe  hyperbilirubinemia,  which  was  not  assessed  in  the  study.  Further  studies
are  necessary  to  conﬁrm  this  combination.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Validac¸ão  de  um  nomograma  de  bilirrubina  transcutânea  para  identiﬁcac¸ão  de
hiperbilirrubinemia  neonatal  em  neonatos  a  termo  e  pré-termo  tardios  saudáveis  na
China:  um  estudo  multicêntrico
Resumo
Objetivo:  validar  de  forma  prospectiva  um  nomograma  de  bilirrubina  transcutânea  (BTc)  para
identiﬁcar  hiperbilirrubinemia  grave  em  neonatos  a  termo  e  pré-termo  tardios  saudáveis  na
China.
Métodos:  foi  realizado  um  estudo  multicêntrico  que  incluiu  9174  neonatos  a  termo  e  pré-termo
tardios saudáveis  em  oito  unidades  da  China.  Foram  realizadas  dosagens  de  BTc  utilizando  um
bilirrubinômetro.  Os  valores  de  BTc  foram  trac¸ados  em  um  nomograma  de  BTc  para  identiﬁcar
a  capacidade  de  predic¸ão  de  hiperbilirrubinemia  signiﬁcativa.
Resultados:  972  recém-nascidos  (10,6%)  desenvolveram  hiperbilirrubinemia  signiﬁcativa.  O
percentil  40  de  nosso  nomograma  pode  identiﬁcar  todos  os  recém-nascidos  com  risco  de  hiper-
bilirrubinemia  signiﬁcativa,  porém  com  baixo  valor  preditivo  positivo  (VPP)  (18,9%).  De  453
recém-nascidos  acima  do  percentil  95,  275  recém-nascidos  desenvolveram  posteriormente
hiperbilirrubinemia signiﬁcativa,  com  VPP  elevado  (60,7%),  porém  com  baixa  sensibilidade
(28,3%).  O  percentil  de  75  foi  altamente  especíﬁco  (81,9%)  e  moderadamente  sensível  (79,8%).
A  área  sob  a  curva  (ASC)  de  nosso  nomograma  de  BTc  foi  de  0,875.
Conclusões:  este  estudo  validou  o  nomograma  de  BTc,  que  pode  ser  utilizado  para  prever
hiperbilirrubinemia signiﬁcativa  em  neonatos  a  termo  e  pré-termo  tardios  saudáveis  na  China.
Contudo,  combinar  o  nomograma  de  BTc  e  fatores  de  risco  clínicos  pode  melhorar  a  precisão
de  predic¸ão  da  hiperbilirrubinemia  grave,  o  que  não  foi  avaliado  neste  estudo.  São  necessários
estudos  adicionais  para  conﬁrmar  essa  combinac¸ão.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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yperbilirubinemia  causes  severe  damage  in  term  and  late-
reterm infants;  the  American  Academy  of  Pediatrics  (AAP)
as formulated  methods  of  surveillance,  prediction,  and
herapy.1 In  China,  bilirubin  encephalopathy  continues  to
ccur, and  348  cases  were  reported  from  28  hospitals  from
anuary to  December  of  2009.2 Therefore,  the  identiﬁcation
f neonates  at  risk  of  developing  signiﬁcant  hyperbilirubine-
ia and  prevention  of  bilirubin  encephalopathy  remain  a
igh priority  among  public  health  institutions.
The  total  serum  bilirubin  (TSB)  level  after  birth  was  plot-
ed on  an  hour-speciﬁc  nomogram  by  Bhutani  et  al.,  and
s a  valuable  method  for  assessing  the  risk  of  subsequent
evere hyperbilirubinemia.3 The  AAP  has  recommended  the
easurement of  TSB  in  a  predischarge  newborn  population
or identiﬁcation  of  severe  hyperbilirubinemia,  based  on  the
hutani’s nomogram.1 However,  measurements  of  TSB  levels
emain an  invasive,  stressful,  and  time-consuming  proce-
ure. Transcutaneous  bilirubin  (TcB)  is  less  time-consuming,
nd can  be  used  to  screen  for  the  need  for  blood  sampling
or serum  bilirubin  level,  and  thus  reduce  the  measure-
ents of  TSB.4 The  values  of  TcB  after  birth  have  also
een plotted  on  an  hour-speciﬁc  TcB  nomogram  to  pre-
ict severe  hyperbilirubinemia  in  term  and  late-preterm
E
m
snfants.5 These  hour-speciﬁc  TcB  nomograms  assessed  pre-
est predictive  ability  using  retrospective  data  from  the
ame developed  TcB  nomogram.6 Theoretically,  a  predictive
omogram should  be  developed  in  one  sample  and  vali-
ated in  another,  and  some  studies  prospectively  assessed
he post-test  predictivity  of  TcB  nomograms  in  different
amples.7,8 The  after-effect  evaluation  of  the  constructed
cB nomogram  is  very  important  to  explore  the  possibility
or future  clinical  application.
In  2010,  the  authors  developed  an  hour-speciﬁc  TcB
omogram based  on  TcB  levels  for  the  ﬁrst  168  h  after  birth  in
,035 healthy  term  and  late-preterm  infants.9 Subsequently,
hey have  conducted  a multicenter  study  to  verify  the  pre-
ictive value  of  the  constructed  TcB  nomogram  to  identify
evere hyperbilirubinemia  in  healthy  term  and  late-preterm
nfants.
ethods
ettingight  hospitals,  including  two  general  hospitals  and  six
aternity hospitals,  participated  in  the  study.  They  were
elected because  they  are  the  main  tertiary  centers  in
275
Table  1  Number  of  neonates  from  each  hospital  partici-
pating in  the  study.
Collaborative  units  Participants,  n
Nanjing  Maternity  and  Child  Healthcare
Hospital,  Nanjing  Medical  University
1,796
Inner Mongolia  Maternal  and  Child
Healthcare  Hospital
1,703
The First  Afﬁliated  Hospital  of  Xinjiang
Medical  University
1,394
Changzhou  Maternal  and  Child
Healthcare  Hospital
1,271
Gynecology and  Obstetrics  Hospital,
Fudan  University
1,046
The Fifth  People’s  Hospital  of  Shenzhen  927
Guangxi Maternal  and  Child  Health
Hospital
565
Guangdong  Maternal  and  Children’s 472
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eTcB  nomogram  for  identifying  neonatal  hyperbilirubinemia  
their  areas  and  because  they  agreed  to  participate  in  this
study. The  Ethics  Committee  of  the  Nanjing  Maternity  and
Child Healthcare  Hospital  of  the  Nanjing  Medical  University
approved the  study  and  it  was  adopted  by  each  participating
center. The  Nanjing  Maternity  and  Child  Healthcare  Hospital
of the  Nanjing  Medical  University  performed  the  statistical
analysis of  the  collaborative  data.  The  Children’s  Hospital
of Fudan  University  did  not  participate  in  this  survey,  but
served as  a  coordinating  center  and  supervised  the  study.
Selection  of  participants
This  multicenter  prospective  study  was  conducted  between
August 1,  2010,  and  December  31,  2011.  Neonates  with  ges-
tational  age  (GA)  ≥  35  weeks  and  birth  weight  ≥  2,000  g
were included,  and  all  sick  neonates  who  were  admitted  to
the intensive  care  unit  and  those  who  required  phototherapy
before discharge  were  excluded.  The  decision  to  use  pho-
totherapy was  made  by  the  attending  physicians  according
to AAP  guidelines.1 No  prophylactic  intervention  for  hyper-
bilirubinemia was  used.
Measurements  of  TcB  and  TSB
TcB  measurements  were  performed  with  a  transcutaneous
jaundice meter  model  JM-103  (Minolta  -  Osaka,  Japan).  A
single device  was  used  for  all  measurements  in  each  partici-
pating unit.  All  measurements  were  performed  by  trained
physicians according  to  the  instructions  of  the  manufac-
turer and  using  the  standard  technique.10 The  physicians
obtained TcB  measurements,  which  were  performed  at  two
sites (the  forehead  and  mid-sternum),  and  the  mean  of  both
measurements was  calculated.  According  to  previous  stud-
ies, the  JM-103  is  less  accurate  at  TcB  levels  >  222  mol/L,
which were  conﬁrmed  with  a  TSB  measurement.10 The
blood samples  (50  L)  were  drawn  by  heel  stick,  and  spe-
cial care  was  taken  to  avoid  exposure  of  the  collected
samples to  light.  TSB  assessment  was  performed  in  the  clin-
ical chemistry  laboratory  of  each  participating  unit.  Skilled
physicians performed  the  TSB  measurements  using  a  UNI-
STAT reﬂectance  bilirubinometer  (Reichert-Jung  -  Buffalo,
NY, USA),  according  to  the  manufacturer’s  instructions.  Sig-
niﬁcant hyperbilirubinemia  was  deﬁned  as  TSB  above  the
95th percentile  for  age  (high-risk  zone),  according  to  the
hour-speciﬁc percentile  nomogram  presented  by  the  AAP
guidelines.1
Follow-up  of  studied  neonates
In  each  participating  unit,  the  physicians  obtained  TcB  mea-
surements between  7:30  a.m.  and  8:00  p.m.,  and  then  at
time intervals  of  12  ±  2  h.  At  least  six  measurements  were
obtained for  each  infant.  A  follow-up  evaluation  within  24  h
to 96  h  after  discharge  was  offered  to  all  neonates,  depend-
ing on  TcB  levels  before  discharge,  which  were  described
in the  authors’  previous  study.9 All  perinatal  and  postpar-
tum data  of  neonates  were  recorded  in  a  single  database
for each  unit  during  the  study  period.  Each  participating
unit adopted  the  same  clinical  protocol  study,  method  for
sample collection,  patient  recruitment,  and  measurements
b
n
e
dHospital,  Guangzhou  Medical  College
Total 9,174
f  TcB  and  TSB.  The  coordinating  center  trained  the  investi-
ators and  supervised  the  implementation,  so  that  the  data
rom each  unit  could  be  pooled.
tatistical  analysis
ata  collected  in  the  eight  participating  units  were  pooled
y the  Nanjing  Maternity  and  Child  Healthcare  Hospital
f the  Nanjing  Medical  University,  which  conducted  the
tatistical analysis.  These  data  were  entered  into  a custom-
esigned spreadsheet  (Microsoft  Excel  2003,  Microsoft
orporation - Redmond,  WA,  USA)  and  checked  for  complete-
ess, consistency,  and  accuracy  by  two  researchers  (Qing  Sun
nd Xiaoyue  Dong).  After  checking  and  verifying  these  data,
he TcB  values  were  plotted  on  the  previously  constructed
cB nomogram,  separately  by  two  researchers  (Qing  Sun  and
iaofan Sun).9 The  sensitivity,  speciﬁcity,  positive  predictive
alues (PPV),  negative  predictive  values  (NPV),  and  positive
ikelihood ratio  (PLR)  were  calculated  for  the  40th,  75th, and
5th percentile  of  the  TcB  nomogram.  Receiver  operating
haracteristic (ROC)  curve  analysis  was  performed  with  the
tatistical Package  for  Social  Sciences  (SPSS),  version  16.0
SPSS Inc.  - Chicago,  IL,  USA),  which  was  used  to  assess  the
redictive ability  of  the  TcB  nomogram.
esults
ight  hospitals  participated  in  the  multicenter  study.  The
umber of  neonates  from  each  hospital  are  listed  in  Table  1;
,174 neonates  (5,385  males  and  3,789  females),  of  whom
45 (10.3%)  were  late-preterm,  were  enrolled  in  the  study.
ean GA  was  38.6  ±  2.9  weeks  and  mean  birth  weight  was
,875 ±  412  g;  5,275  (57.5%)  neonates  were  born  by  cesarean
ection. Regarding  feeding,  3,165  (34.5%)  neonates  were
xclusively breast-fed,  and  3,376  (36.8%)  were  exclusively
ottle-fed. Of  the  total  population  studied,  514  (5.6%)
eonates were  small  for  gestational  age,  661  (7.2%)  experi-
nced a  weight  loss  greater  than  10%,  and  147  (1.6%)  were
iagnosed as  having  ABO  incompatibility.
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Table  2  Predictive  characteristics  of  percentile  values  of  predischarge  TcB  for  subsequent  signiﬁcant  hyperbilirubinemia.
Predischarge  TcB  Signiﬁcant
hyperbilirubinemia
Predictive  characteristics
Percentile  Number
(9174)
Present
(972)
Absent
(8202)
Sensitivity  (%)  Speciﬁcity  (%)  PPV  (%)  NPV  (%)
Above  the  95th percentile  453  275  178  28.3  97.8  60.7  92.0
Below the  95th percentile  8,721  697  8,024
Above the  75th percentile  2,258  776  1,482  79.8  81.9  34.4  97.2
Below the  75th percentile  6,916  196  6,720
Above the  40th percentile  5,137  972  4,165  100.0  49.2  18.9  100.0
Below the  40th percentile 4,037  0  4,037
NPV, negative predictive value; PPV, positive predictive value; TcB, tra
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Figure  1  ROC  curve  for  predicting  signiﬁcant  hyperbilirubine-
mia using  the  predischarge  hour-speciﬁc  TcB  nomogram.  ROC,
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ilirubin.
Regarding  the  percentiles,  972/9,174  (10.6%)  neonates
ere above  the  95th percentile  based  on  AAP  guidelines
signiﬁcant hyperbilirubinemia).  In  453  (4.9%)  neonates,
redischarge TcB  was  >  95th percentile  (Table  2).  Of  these,
75 neonates  subsequently  developed  signiﬁcant  hyper-
ilirubinemia (PPV:  60.7%,  sensitivity:  28.3%).  In  4,037
36.8%) neonates,  predischarge  TcB  was  <  40th percentile;
one of  whom  developed  signiﬁcant  hyperbilirubinemia
NPV: 100.0%  and  speciﬁcity:  49.2%).  The  75th percentile
urve showed  a  sensitivity  of  79.8%  and  an  NPV  of  97.2%;
he speciﬁcity  was  81.9%.  The  AUC  for  predischarge  TcB
ercentiles was  0.875  (Figure  1).
The  PLR  that  determines  the  risk  assessment  for  sub-
equent signiﬁcant  hyperbilirubinemia  for  each  risk  zone
s presented  in  Table  3.  Among  453  neonates  with  pre-
ischarge TcB  in  the  high-risk  zone  (>  95th percentile),
75 (60.7%)  subsequently  developed  signiﬁcant  hyperbiliru-
inemia. Conversely,  178  newborns  in  the  95th percentile
id not  develop  signiﬁcant  hyperbilirubinemia  (PLR  =  12.9)
Table 3).  Of  the  1,805  newborns  in  the  upper-intermediate
a
t
0
bnscutaneous bilirubin.
isk  zone  (76th to  95th percentile),  501  (27.8%)  jumped  to
he high-risk  zone  (PLR  =  4.4).  Of  the  2,879  neonates  in
he lower-intermediate  risk  zone  (40th to  75th percentile),
96 (6.8%)  climbed  to  the  high-risk  zone  (PLR  =  2.0).  Of  the
,037 neonates  in  the  low-risk  zone  (<  40th percentile),  none
oved upwards  into  the  high-risk  zone  (Table  3).
iscussion
SB  measurements  are  an  invasive  procedure  that  involves
ain, neonatal  stress,  and  risk  of  infection.  A  noninvasive
etermination of  bilirubin  concentrations  (TcB)  is  advanta-
eous, and  is  suitable  for  universal  neonatal  screening.11
he  new  generation  of  noninvasive  TcB-measuring  devices
BiliCheckTM and  JM-103)  have  presented  good  correla-
ions with  TSB  measurements  (BiliCheckTM:  0.8212,  JM-103:
.8686).12 Recently,  some  studies  developed  predictive
omograms based  on  measurements  of  TcB  or  TSB  to  assess
he risk  for  signiﬁcant  hyperbilirubinemia  in  healthy  term
nd late-preterm  infants.13--18 The  results  showed  that  the
cB nomogram  was  equivalent  to  the  TSB  nomogram,  and
oth could  be  used  to  identify  subsequent  signiﬁcant  hyper-
ilirubinemia.
A predictive  nomogram  should  be  developed  in  one  sam-
le and  validated  in  another.  The  present  study  was  a
ulticenter study  to  verify  the  predictive  value  of  the  TcB
omogram constructed  in  2010.9 The  result  showed  that  the
UC was  0.875,  which  was  lower  than  the  pre-test  pre-
ictive ability  in  the  previous  study  (AUC  =  0.920).  The
reviously constructed  TcB  nomogram  was  developed  from
 single  hospital,  which  could  not  represent  the  demo-
raphic characteristics  of  the  Chinese  neonatal  population.
he multicenter  study  included  eight  units,  which  showed
ifferent genetic  and  environmental  features.  Therefore,
 population-based  TcB  nomogram  should  be  constructed,
hich should  show  a  better  predictive  ability.
The  rate  of  TcB  increase  is  affected  by  smaller  ges-
ational age,  blood  incompatibilities,  glucose-6-phosphate
ehydrogenase  deﬁciency,  increased  weight  loss,  and  exclu-
ive  breastfeeding.19 Therefore,  risk  factors  should  been
ssessed when  planning  appropriate  follow-up  strategies
ccording to  the  predischarge  TcB. Six  centers  assessed
he predictive  value  of  predischarge  TcB,  and  the  AUC  was
.86; however,  combined  clinical  risk  factors  (earlier  GA,
ruising, positive  direct  antiglobulin  test,  Asian  race,  exclu-
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Table  3  Predictive  ability  of  percentile  values  of  predischarge  TcB  for  subsequent  signiﬁcant  hyperbilirubinemia.
Predischarge  TcB  Signiﬁcant
hyperbilirubinemia
Predictive ability
Risk  zone  Percentile  Number
(9,174)
Present
(972)
Absent
(8,202)
Probability  of
disease
PLR
High-risk  >  95th 453  275  178  60.7%  12.9
Upper-intermediate  76th-95th 1,805  501  1,304  27.8%  4.4
Lower-intermediate  40th-75th 2,879  196  2,683  6.8%  2.0
Low-risk  <  40th 4,037  0  4,037  0.0%  0
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RPLR, positive likelihood ratio; TcB, transcutaneous bilirubin
sive  breastfeeding,  blood  type  incompatibility,  and  jaundice
extent) was  better  (AUC  =  0.95).21 Another  study  evaluated
the predictive  performance  of  predischarge  bilirubin  risk
zone (AUC  =  0.88);  however,  combined  clinical  risk  factors
(GA, and  percentage  of  weight  loss  per  day  on  the  ﬁrst  two
days) showed  better  accuracy  (AUC  =  0.96).22 Thus,  the  risk
factors for  developing  signiﬁcant  hyperbilirubinemia  in  the
Chinese neonatal  population  should  have  been  investigated
in combination  with  a  TcB  nomogram,  which  could  improve
the predictive  accuracy.
The study  has  some  limitations.  Firstly,  the  previous  TcB
nomogram was  constructed  from  a  single,  tertiary-care  cen-
ter, which  does  not  represent  population-based  study  data.
Secondly, the  previous  TcB  nomogram  did  not  combine  the
TcB nomogram  with  other  clinical  risk  factors,  such  as  GA  and
exclusive breastfeeding,  which  may  improve  the  prediction
of subsequent  hyperbilirubinemia.  Due  to  the  relative  limi-
tations of  previous  TcB  nomogram,  the  authors  are  currently
conducting a  multicenter  study  (ClinicalTrials.gov  Identiﬁer:
NCT01763632), in  which  17  hospitals  in  China  will  participate
from January  to  December,  2013,  to  develop  an  hour-speciﬁc
TcB nomogram.  The  constructed  TcB  nomogram,  which  will
combine predischarge  TcB  with  other  clinical  risk  factors,
may better  represent  the  Chinese  neonatal  population.
Conclusion
The  multicenter  study  validated  the  TcB  nomogram,  which
is a  useful  tool  for  predicting  subsequent  severe  hyperbiliru-
binemia in  Chinese  healthy  term  and  late-preterm  infants.
However, the  study  did  not  combine  predischarge  TcB  with
clinical risk  factors  (such  as  GA,  exclusive  breastfeeding,
cephalhematoma,  signiﬁcant  bruising,  or  previous  sibling
with jaundice)  to  determine  the  risk  for  healthy  term  and
late-preterm infants  developing  subsequent  severe  hyper-
bilirubinemia. Further  studies  are  necessary  to  conﬁrm  this
combination.
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